MA27075A1 - Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) - quinazoline - Google Patents
Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) - quinazolineInfo
- Publication number
- MA27075A1 MA27075A1 MA27623A MA27623A MA27075A1 MA 27075 A1 MA27075 A1 MA 27075A1 MA 27623 A MA27623 A MA 27623A MA 27623 A MA27623 A MA 27623A MA 27075 A1 MA27075 A1 MA 27075A1
- Authority
- MA
- Morocco
- Prior art keywords
- tetrahydroisoquinol
- quinazoline
- dimethoxy
- pyridyl
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DEPOSANT Société dite: PFIZER INC. REVENDICATION DE PRIORITES GB 11 Octobre 2001 0124455.7 Voir en annexe le titre de l'invention et le texte de l'abrégé Formulations pharmaceutiques pour la libération contrôlée de la 4-amino-6,7-diméthoxy-2-(5-méthanesulfonamido-1,2,3, 4-tétrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline La présente invention propose une formulation pharmaceutique à libération contrôlée pour administration orale, comprenant de la 4-amino-6,7-diméthoxy-2-(5-méthanesulfonamido-1,2,3,4-tétrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline, ou un de ses sels pharmaceutiquement acceptables, et un adjuvant, diluant ou support pharmaceutiquement acceptable, ladite formulation étant caractérisée en ce qu'elle est adaptée a libérer au moins 50 % en poids de la 4-amino-6,7-diméthoxy-2-(5-méthane-sulfonamido-1,2,3,4-tétrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline, ou de son sel pharmaceutiquement acceptable, au bout de 6 heures dans l'Appareil 1 décrit dans la Pharmacopée des Etats-Unis d'Amérique 24 (2000), pages 1941-1943, comprenant des récipients de 1 litre, des paniers à mailles no. 40 (ouvertures de 0,4 mm), à une vitesse de rotation de 100 tr/min, et avec un milieu de dissolution consistant en 900 ml d'acide chlorhydrique 0,01 M contenant 0,7 % en poids / volume de chlorure de sodium à 37o.C. Les formulations conformes à la présente invention conviennent au traitement de l'hyperplasie prostatique bénigne (HPB).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0124455.7A GB0124455D0 (en) | 2001-10-11 | 2001-10-11 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27075A1 true MA27075A1 (fr) | 2004-12-20 |
Family
ID=9923660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27623A MA27075A1 (fr) | 2001-10-11 | 2004-04-08 | Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) - quinazoline |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1434570B8 (fr) |
| JP (1) | JP4131471B2 (fr) |
| KR (1) | KR20050032510A (fr) |
| CN (1) | CN1568180A (fr) |
| AP (1) | AP2004003001A0 (fr) |
| AR (1) | AR036782A1 (fr) |
| AT (1) | ATE303135T1 (fr) |
| BR (1) | BR0213196A (fr) |
| CA (1) | CA2461168A1 (fr) |
| CO (1) | CO5560534A2 (fr) |
| DE (1) | DE60205925T2 (fr) |
| DK (1) | DK1434570T3 (fr) |
| DO (1) | DOP2002000464A (fr) |
| EA (1) | EA006168B1 (fr) |
| ES (1) | ES2246017T3 (fr) |
| GB (1) | GB0124455D0 (fr) |
| GT (1) | GT200200184A (fr) |
| HR (1) | HRP20040261A2 (fr) |
| HU (1) | HUP0600064A3 (fr) |
| IL (1) | IL160969A0 (fr) |
| IS (1) | IS7179A (fr) |
| MA (1) | MA27075A1 (fr) |
| MX (1) | MXPA04003293A (fr) |
| NO (1) | NO20041520L (fr) |
| OA (1) | OA12709A (fr) |
| PA (1) | PA8556001A1 (fr) |
| PE (1) | PE20030551A1 (fr) |
| PL (1) | PL369666A1 (fr) |
| SV (1) | SV2004001279A (fr) |
| UY (1) | UY27477A1 (fr) |
| WO (1) | WO2003032956A1 (fr) |
| ZA (1) | ZA200401976B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| MY186048A (en) | 2013-03-14 | 2021-06-17 | Cytokinetics Inc | Heterocyclic compounds and their uses |
| KR101943592B1 (ko) | 2017-08-31 | 2019-01-30 | 조현우 | 데이터 마이닝 기법을 이용한 전자가계부 시스템 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69008526T2 (de) * | 1990-07-02 | 1994-08-18 | Bend Res Inc | Asymmetrische mikroporöse Kügelchen für regulierbare Freigabe. |
| FR2752737B1 (fr) * | 1996-08-29 | 1998-10-02 | Synthelabo | Comprime a liberation controlee de chlorhydrate d'alfuzosine |
| GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
| CN1214029C (zh) * | 2000-03-03 | 2005-08-10 | 辉瑞大药厂 | 4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉甲磺酸盐及多晶形物 |
-
2001
- 2001-10-11 GB GBGB0124455.7A patent/GB0124455D0/en not_active Ceased
-
2002
- 2002-09-12 DO DO2002000464A patent/DOP2002000464A/es unknown
- 2002-09-17 GT GT200200184A patent/GT200200184A/es unknown
- 2002-09-30 PL PL02369666A patent/PL369666A1/xx not_active Application Discontinuation
- 2002-09-30 JP JP2003535760A patent/JP4131471B2/ja not_active Expired - Fee Related
- 2002-09-30 WO PCT/IB2002/004040 patent/WO2003032956A1/fr active IP Right Grant
- 2002-09-30 OA OA1200400094A patent/OA12709A/en unknown
- 2002-09-30 DK DK02775048T patent/DK1434570T3/da active
- 2002-09-30 KR KR1020047005316A patent/KR20050032510A/ko not_active Application Discontinuation
- 2002-09-30 EP EP02775048A patent/EP1434570B8/fr not_active Expired - Lifetime
- 2002-09-30 DE DE60205925T patent/DE60205925T2/de not_active Expired - Lifetime
- 2002-09-30 BR BR0213196-0A patent/BR0213196A/pt not_active IP Right Cessation
- 2002-09-30 AT AT02775048T patent/ATE303135T1/de not_active IP Right Cessation
- 2002-09-30 HU HU0600064A patent/HUP0600064A3/hu unknown
- 2002-09-30 CN CNA02820042XA patent/CN1568180A/zh active Pending
- 2002-09-30 ES ES02775048T patent/ES2246017T3/es not_active Expired - Lifetime
- 2002-09-30 AP APAP/P/2004/003001A patent/AP2004003001A0/en unknown
- 2002-09-30 MX MXPA04003293A patent/MXPA04003293A/es active IP Right Grant
- 2002-09-30 EA EA200400431A patent/EA006168B1/ru not_active IP Right Cessation
- 2002-09-30 IL IL16096902A patent/IL160969A0/xx unknown
- 2002-09-30 CA CA002461168A patent/CA2461168A1/fr not_active Abandoned
- 2002-10-09 AR ARP020103805A patent/AR036782A1/es unknown
- 2002-10-09 UY UY27477A patent/UY27477A1/es not_active Application Discontinuation
- 2002-10-09 PE PE2002000996A patent/PE20030551A1/es not_active Application Discontinuation
- 2002-10-10 SV SV2002001279A patent/SV2004001279A/es not_active Application Discontinuation
- 2002-10-10 PA PA20028556001A patent/PA8556001A1/es unknown
-
2004
- 2004-03-11 ZA ZA200401976A patent/ZA200401976B/en unknown
- 2004-03-11 IS IS7179A patent/IS7179A/is unknown
- 2004-03-17 HR HR20040261A patent/HRP20040261A2/hr not_active Application Discontinuation
- 2004-03-18 CO CO04025929A patent/CO5560534A2/es not_active Application Discontinuation
- 2004-04-05 NO NO20041520A patent/NO20041520L/no unknown
- 2004-04-08 MA MA27623A patent/MA27075A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27153A1 (fr) | Formulations pharmaceutiques de derives de platine | |
| MA26700A1 (fr) | FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION. | |
| MA27444A1 (fr) | Derives d'isothiazole et d'isoxazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
| HUP0402004A2 (hu) | Módosított hatóanyag-leadású tamszulozintabletták | |
| DZ2549A1 (fr) | Compositions pharmaceutiques contenant de l'hémisulfate d'élétriptan. | |
| AU3913297A (en) | Pleasant-tasting aqueous liquid composition of a bitter-tasting drug | |
| TNSN00232A1 (fr) | Derives de 2,4-diaminopyrimidine nouveaux, et compositions les contenant | |
| BE899635A (fr) | Compositions pharmaceutiques. | |
| BE900660A (fr) | Composition therapeutique pour le traitement des sequelles d'intoxication. | |
| TNSN07145A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| MA27054A1 (fr) | Formulation de suspension orale stabilisee | |
| MA28742B1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique | |
| MA27980A1 (fr) | Nouvelle composition | |
| MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
| MA27075A1 (fr) | Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) - quinazoline | |
| CA2503211A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire | |
| Chiang et al. | Asymptomatic hypertension in the ED | |
| JP2002193839A (ja) | ココア製剤 | |
| TNSN04054A1 (fr) | Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline | |
| MA28224A1 (fr) | Nitro-oxyderives de medicaments contre l'hypertension. | |
| MA26876A1 (fr) | Mesylate et formes polymorphes de 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline | |
| MA26698A1 (fr) | Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation | |
| FR2869539A1 (fr) | Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose | |
| JPS6466175A (en) | Leukotriene antagonist | |
| ECSP045045A (es) | Formulaciones farmacéuticas de liberación controlada que comprende 4-amino-6,7-dimetoxi-2-(5-metanosulfonamido-1,2,3,4-tetrahidroisoquinol-2-il)-5-(2-piridil)quinazolina |